CorMedix Inc. (CRMD) vs Nuvectis Pharma, Inc. (NVCT)

A side-by-side comparison of CorMedix Inc. and Nuvectis Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
CorMedix Inc. logo
CRMD
CorMedix Inc.
$566M
$7.22HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Nuvectis Pharma, Inc. logo
NVCT
Nuvectis Pharma, Inc.
$547M
$20.60HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT

Total return — CRMD vs NVCT

growth of $100 · dividends reinvested · last 5y
CRMD +71.6% (+11.4%/yr)NVCT +558.2% (+45.8%/yr)NVCT compounded faster over this window
200400600800Start $1002023202420252026$172$658
CRMD NVCT

CRMD vs NVCT: by the numbers

  • •CRMD is the larger company ($566M vs $547M market cap).
  • •CRMD is profitable (40.49% net margin) while NVCT runs a net loss (0.00%).

Metrics side by side

Valuation

MetricCRMDNVCT
P/E ratio3.39N/A
Forward P/E14.59N/A
P/S ratio1.23N/A
P/B ratio1.2360.18
EV / EBITDA1.80N/A
FCF yield44.18%N/A

Profitability

MetricCRMDNVCT
Gross margin82.78%0.00%
Operating margin46.95%0.00%
Net margin40.49%0.00%
ROE40.62%-306.61%
ROIC27.87%-317.86%

Growth (annualized)

MetricCRMDNVCT
Revenue CAGR (5Y)352.03%N/A
Total return CAGR (5Y)9.70%N/A

Frequently asked

Is CRMD or NVCT more profitable?
CRMD runs the higher net margin — CRMD at 40.49% versus NVCT at 0.00%.

Go deeper

Full CRMD analysisFull NVCT analysisInteractive comparison tool

Dig into the metrics

CorMedix P/E ratioCorMedix ROENuvectis Pharma ROECorMedix operating marginNuvectis Pharma operating marginCorMedix revenue growthNuvectis Pharma revenue growthCorMedix free cash flowNuvectis Pharma free cash flow

CorMedix & Nuvectis Pharma appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksHighest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.